| Myasthenia Gravis, Generalized
Uplinza vs Vyvgart
Side-by-side clinical, coverage, and cost comparison for myasthenia gravis, generalized.Deep comparison between: Uplizna vs Vyvgart with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVyvgart has a higher rate of injection site reactions vs Uplizna based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vyvgart but not Uplizna, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Uplizna
Vyvgart
At A Glance
IV infusion
Every 6 months
CD19-directed cytolytic antibody
IV infusion
Once weekly for 4 weeks per cycle
FcRn antagonist
Indications
- Neuromyelitis Optica
- Immunoglobulin G4-Related Disease
- Myasthenia Gravis, Generalized
- Myasthenia Gravis, Generalized
Dosing
Neuromyelitis Optica, Immunoglobulin G4-Related Disease, Myasthenia Gravis, Generalized Initial dose: 300 mg IV infusion, followed 2 weeks later by a second 300 mg IV infusion; subsequent doses: 300 mg IV infusion every 6 months starting 6 months from first infusion; premedicate with a corticosteroid (methylprednisolone 80-125 mg IV), antihistamine (diphenhydramine 25-50 mg oral), and antipyretic (acetaminophen 500-650 mg oral) before each infusion; dilute in 250 mL 0.9% Sodium Chloride and infuse over approximately 90 minutes.
Myasthenia Gravis, Generalized 10 mg/kg (1200 mg if >=120 kg) as IV infusion over 1 hour once weekly for 4 weeks; subsequent cycles based on clinical evaluation.
Contraindications
- History of life-threatening infusion reaction to inebilizumab-cdon or any excipient
- Active hepatitis B infection (confirmed by positive HBsAg and anti-HBV tests)
- Active or untreated latent tuberculosis
- Serious hypersensitivity to efgartigimod alfa products or any excipient of VYVGART
Adverse Reactions
Most common (>=10%) Urinary tract infection, nasopharyngitis, infusion-related reaction, arthralgia, headache, lymphopenia
Serious Infusion reactions, infections, reduction in immunoglobulins
Most common (>=5%) Respiratory tract infection, headache, urinary tract infection, paraesthesia, myalgia
Postmarketing Hypersensitivity reactions including anaphylaxis and hypotension, infusion-related reactions
Pharmacology
CD19-directed humanized afucosylated IgG1 monoclonal antibody; binds CD19 on pre-B and mature B lymphocytes and induces antibody-dependent cellular cytolysis, depleting B-cell counts within 8 days of infusion.
Efgartigimod alfa-fcab is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), reducing circulating IgG levels and AChR autoantibody levels in patients with generalized myasthenia gravis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Uplizna
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (9/12)
Vyvgart
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Uplizna
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Vyvgart
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Uplizna
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Vyvgart
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Amgen By Your Side Copay Assistance Program: UpliznaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Myasthenia Gravis - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
UpliznaView full Uplizna profile
VyvgartView full Vyvgart profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.